Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

PHASE4TerminatedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

May 13, 2022

Study Completion Date

May 30, 2022

Conditions
Covid19Thrombosis
Interventions
DRUG

Apixaban 2.5 MG

Apixaban 2.5mg twice daily for 30 days

DRUG

Placebo

placebo twice daily for 30 days

Trial Locations (4)

Unknown

Hospital Maternidade São Vicente de Paulo, Barbalha

Hospital Universitário São Francisco de Assis, Bragança Paulista

Hospital Israelita Albert Einstein, São Paulo

Hospital Santa Paula, São Paulo

All Listed Sponsors
collaborator

Hospital Israelita Albert Einstein

OTHER

collaborator

Hospital do Coracao

OTHER

collaborator

Hospital Sirio-Libanes

OTHER

collaborator

Hospital Moinhos de Vento

OTHER

collaborator

Hospital Alemão Oswaldo Cruz

OTHER

collaborator

Beneficência Portuguesa de São Paulo

OTHER

collaborator

Brazilian Research In Intensive Care Network

NETWORK

lead

Brazilian Clinical Research Institute

OTHER

NCT04746339 - Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 | Biotech Hunter | Biotech Hunter